Dose equivalence between different incretin analogues is a weak concept. The molecules differ in structure, half-life, receptor selectivity, and in what has been studied clinically. One mg of semaglutide is not equivalent to one mg of something else in any meaningful sense.
I have separated what I observed from what I concluded, which does not always happen.
Where I part company with post #6, and it is a narrow parting.
The question underneath steady state is usually "how would I tell?" rather than "what is true?", and that one has a method attached to it.
Write down what you would expect to see under each hypothesis before you collect anything. If they predict the same observation, collecting it will not help.
Post #13 and I disagree about the size of the effect, not about the direction.
There is no published evidence about slower escalation because nobody studied it. That means the trials support not going faster and are silent on going slower, which is a different claim from "slower is fine".
Useful. I have added it to my own notes with the date on it.
Before the thread moves on from steady state — what is the sample size behind the claim? I am not being difficult; I have seen the same figure quoted from an n of four and from an n of four hundred.
Read the full topic (36 posts)
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Follow-up: Why "dose equivalence" between different incretin analogues is a weak concept
Asking directly, because I could not find a straight answer: Why "dose equivalence" between different incretin analogues is a weak concept I have read the maintained page on this and I still have a gap, so I…
|
+7 | 11 | 26k | 9mo |
|
Stepping down deliberately, and how to do it without losing progress
Stepping down deliberately, and how to do it without losing progress — setting out what I have, and where I think it stops being reliable. Practical question with the units stated, because I have seen how…
|
+98 | 102 | 26k | 3mo |
|
How the published trials escalated, tabulated side by side — does this still hold?
Asking directly, because I could not find a straight answer: How the published trials escalated, tabulated side by side — does this still hold? Asking about published trials escalated directly, because I have…
|
2 | 8.9k | 9mo | |
|
Coming back to: Where the four-week escalation interval comes from, and what it is not
Posting this under the heading it deserves: Where the four-week escalation interval comes from, and what it is not Everything below is what sits behind that. Four-week escalation interval — I have the…
|
+44 | 48 | 11k | 1d |
|
Reaching a dose and staying there for a year: a longitudinal note
Reaching a dose and staying there for a year: a longitudinal note Writing it up because I had to work it out twice and would rather nobody else did. I have read the maintained page on this and I still have a…
|
2 | 763 | 15mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
[2026 update] What steady state means for the decision to escalate
The question in the title: What steady state means for the decision to escalate I will give what I have already checked below so nobody repeats it. Asking about steady state directly, because I have read four…
|
+127 | 137 | 32k | 8mo |
|
Albumin binding and how it produces a long half-life
Albumin binding and how it produces a long half-life — setting out what I have, and where I think it stops being reliable. A narrow question about albumin binding, deliberately narrow, because the broad…
|
+38 | 44 | 6.6k | 14mo |
|
Cold solution and stinging: the simplest fix
Posting this under the heading it deserves: Cold solution and stinging: the simplest fix Everything below is what sits behind that. An honest uncertainty about cold solution and stinging rather than a…
|
+35 | 39 | 8.2k | 30d |
|
Receptor desensitisation as a tolerance hypothesis, and its weak evidence
Receptor desensitisation as a tolerance hypothesis, and its weak evidence — setting out what I have, and where I think it stops being reliable. Trying to work out what would count as evidence on receptor…
|
+52 | 57 | 25k | just now |
|
Tracking semaglutide's approved indications across jurisdictions, dated — does this still hold?
Tracking semaglutide's approved indications across jurisdictions, dated — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Practical question…
|
+58 | 62 | 49k | 20mo |